Wai Chun Bio-Technology (HKG:0660) expects a net loss of up to HK$13 million for the year ended June 30, down from HK$65.7 million a year prior, a Friday Hong Kong bourse filing said.

The biochemical products maker attributed the forecast to a decline in impairment losses on non-financial assets.